SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。SELECT是一项第三阶段、双盲、安慰剂对照的临床试验，旨在评估常规临床治疗方法确定的硒和维生素E(单独或联合使用)对前列腺癌发病率的影响。应计目标是全国范围内55岁或以上(非裔美国人为50岁或以上)的健康男性32,400人。学习期限为十二年，五年为统一的应计期。参与者将从他们随机分组的时间到试验期结束，根据参与者被随机分组的时间，在7到12年之间接受研究补充。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SELECT is a Phase III, double blind, placebo-controlled clinical trial designed to assess the effect of selenium and vitamin E (individually and in combination) on the incidence of prostate cancer as determined by routine clinical management. The accrual goal is 32,400 healthy men nationwide who are 55 years old or older (age 50 years or older for African-American men). Study duration will be twelve years with a five-year uniform accrual period. Participants will receive study supplements from the time of their randomization until the end of the trial period, between seven and twelve years depending upon when the participant was randomized.